Cancer Immunology Reserch

Cancer Immunol Res. 2026 Sep 9. doi: 10.1158/2326-6066.CIR-26-0070. Online ahead of print. ABSTRACT Myeloid checkpoint blockade as monotherapy often yields limited benefit, suggesting that multiple inhibitory pathways cooperatively sustain myeloid immunosuppression in the tumor microenvironment (TME). However, strategies to concurrently target multiple myeloid checkpoints remain challenging. Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a soluble LILRA/B … Read more

Cancer Immunol Res. 2026 Sep 8. doi: 10.1158/2326-6066.CIR-25-0855. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapies have shown limited promise in solid tumors owing to the immunosuppressive tumor microenvironment. TAK-102 is a next-generation, glypican-3 (GPC3)-targeted CAR T-cell therapy engineered to co-express interleukin-7 (IL-7) and chemokine ligand 19 (CCL19), enhancing T-cell survival and … Read more

Cancer Immunol Res. 2026 Sep 4. doi: 10.1158/2326-6066.CIR-26-0472. Online ahead of print. ABSTRACT The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by restrained function of effector T cells that drives resistance to immunotherapy. While tumor-extrinsic stroma and myeloid cells have been shown to mediate PDAC immune evasion, the role of tumor-intrinsic post-transcriptional … Read more

Cancer Immunol Res. 2026 Sep 4:OF1-OF2. doi: 10.1158/2326-6066.CIR-26-0906. Online ahead of print. ABSTRACT The therapeutic potential of chimeric antigen receptor (CAR) T cells has long been limited by the static nature of the engineered receptor; once manufactured, the cell is committed to a single antigen, unable to respond to the immune evasion and antigen heterogeneity … Read more

Cancer Immunol Res. 2026 Sep 2;14(9):1369. doi: 10.1158/2326-6066.CIR-14-9-WWR. NO ABSTRACT PMID:42682071 | DOI:10.1158/2326-6066.CIR-14-9-WWR

Cancer Immunol Res. 2026 Aug 31. doi: 10.1158/2326-6066.CIR-26-0177. Online ahead of print. ABSTRACT Immune checkpoint blockade (ICB) has markedly improved overall survival in various cancers, but is associated with severe and sometimes fatal immune-related adverse events (irAEs). Current management of irAEs involves discontinuation of ICB therapy and administration of immunosuppressive drugs, such as corticosteroids, which … Read more

Cancer Immunol Res. 2026 Aug 31. doi: 10.1158/2326-6066.CIR-25-1379. Online ahead of print. ABSTRACT The efficacy of immunotherapy in unresectable/recurrent/metastatic head and neck squamous cell carcinoma (U/R/M HNSCC) remains suboptimal compared to primary untreated resectable HNSCC. The immunological and stromal landscape during immunotherapy in U/R/M HNSCC is crucial for understanding drug resistance mechanisms. In this study, … Read more

Cancer Immunol Res. 2026 Aug 31. doi: 10.1158/2326-6066.CIR-26-0104. Online ahead of print. ABSTRACT Tertiary lymphoid structures (TLS) have emerged as critical immune niches within the tumor microenvironment across various cancers. However, their structural organization and functional roles in non-muscle-invasive bladder cancer (NMIBC) remain poorly characterized. In this study, we comprehensively characterized TLS in NMIBC using … Read more

Cancer Immunol Res. 2026 Aug 26. doi: 10.1158/2326-6066.CIR-25-1589. Online ahead of print. ABSTRACT T-cell immune tolerance is established in part through the activity of the Auto-immune Regulator (AIRE) transcription factor in the medullary thymic epithelial cells (mTEC) of the thymus. AIRE induces expression of peripheral tissue-specific self-antigens for presentation to naïve T cells to promote … Read more

Cancer Immunol Res. 2026 Aug 26. doi: 10.1158/2326-6066.CIR-25-1471. Online ahead of print. ABSTRACT Despite the availability of various treatment modalities for liver cancer, its mortality rate remains high. Immunotherapy represents an emerging approach for liver cancer. However, the response rate to single-agent immune checkpoint blockade therapy is suboptimal. Endoplasmic reticulum oxidoreductase 1-alpha (ERO1A), a potential … Read more